trial
Johnson & Johnson announces successful results from trial for myeloma treatment
April 16, 2025Research and Development Johnson & Johnson, Oncology, myeloma, pharma, trial
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …
VALIANT phase 3 trial results highlight potential treatment for rare kidney diseases
October 25, 2024Nephrology, Rare Diseases, rare kidney disease, trial
SOBI and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit …
Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment
August 6, 2024Research and Development Levicept, Rheumatology, osteoarthritis, trial
Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.
Ground-breaking COVID antibody treatment proven to save lives
June 16, 2021Research and Development COVID-19, UK, antibodies, trial
Results from Regeneron’s Recovery trial, investigating a potent monoclonal antibody combination treatment in hospitalised patients with severe COVID-19, have shown …
AstraZeneca antibody fails to prevent COVID in exposed patients
June 15, 2021Manufacturing and Production AstraZeneca, COVID-19, Primary Endpoint, antibody, trial
AstraZeneca has failed to reach the primary endpoint in their Storm Chaser trial, assessing the safety and efficacy of AZD7442, …
UK trial aims to find treatments that can slow or reverse motor neurone disease
January 17, 2020Medical Communications MND, Motor Neurone, clinical trial, motor neurone disease, trial
A UK wide trial called MND-SMART has invited hundreds of people with motor neurone disease (MND) to participate. It will …
Janssen’s Imbruvica shows superiority in Phase 3 trials
June 4, 2019Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial
Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
Celgene trial displays promising results for Crohn’s disease alternative treatment
October 17, 2016Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial
Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …
Takeda begins Phase III dengue vaccine trial
September 8, 2016Research and Development Takeda, Vaccine, dengue, dengue vaccine, phase III, trial
Takeda Pharmaceuticals has announced the initiation of a global Phase III clinical trial to test its live-attenuated tetravalent dengue vaccine …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Sanofi and Regeneron meet endpoint in Phase III Praluent study
March 23, 2016Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial
Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
